Rchr
J-GLOBAL ID：201501010851874820
Update date: Nov. 05, 2024
Kishi Taro
キシ タロウ | Kishi Taro
Affiliation and department：
Homepage URL (1)：
https://kaken.nii.ac.jp/d/r/40536801.ja.html
Research field (1)：
Psychiatry
Research keywords (4)：
エスシタロプラム
, 大うつ病性障害と
, 無作為割付試験
, パロキセチン徐放製剤
Research theme for competitive and other funds (2)：
- 2019 - 2024 Antipsychotic treatment and rehospitalization of schizophrenia patients: a cohort study
- 2013 - 2015 fficacy and tolerability of escitalopram versus paroxetine-CR in Japanese patients with major depressive disorder: a randomized, masked-rater trial
Papers (261)：
-
Tadafumi Kato, Kazuyoshi Ogasawara, Keisuke Motomura, Masaki Kato, Teruaki Tanaka, Yoshikazu Takaesu, Shintaro Nio, Taro Kishi, Mirai So, Kiyotaka Nemoto, et al. Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). Psychiatry and Clinical Neurosciences. 2024
-
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Masakazu Hatano, Shinsuke Kito, Nakao Iwata. Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis. JAMA network open. 2024. 7. 10. e2441159
-
Taro Kishi, Michinori Koebis, Michiko Sugawara, Yuka Kawatsu, Takehiro Taninaga, Nakao Iwata. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review. Translational Psychiatry. 2024
-
Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun-Ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, et al. Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning. BMC psychiatry. 2024. 24. 1. 600-600
-
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Jonas Wilkening, Roberto Goya-Maldonado, Martin Tik, Nolan R Williams, Shinsuke Kito, et al. Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis. Molecular psychiatry. 2024
ｍore...
MISC (147)：
-
岡本直通, 渡邊啓太, 池ノ内篤子, 井形亮平, 小西勇輝, 手銭宏文, 夏山知也, 藤井倫太郎, 岸太郎, 岩田仲生, et al. 5-HTTLPRのs/s遺伝子型を持つ薬物未使用初発うつ病患者における扁桃体サブ領域体積と血中物質の関係:探索的研究. 日本神経化学会大会抄録集(Web). 2022. 65th
-
岸太郎, 松田勇紀, 江角悟, 波多野正和, 三宅誕実, 佐久間健二, 橋本保彦, 川島邦裕, 宮原研吾. 向精神薬の適切な継続・減量・中止等の精神科薬物療法の出口戦略の実践に資する研究 マニュアル作成/双極性障害-気分安定薬. 向精神薬の適切な継続・減量・中止等の精神科薬物療法の出口戦略の実践に資する研究 令和2年度 総括・分担研究報告書(Web). 2021
-
岸太郎, 江角悟, 大矢一登, 奥谷理, 佐久間健二, 野村郁雄, 橋本保彦, 波多野正和, 波多野正和, 松井佑樹, et al. Efficacy and safety of lithium and lamotrigine for the bipolar disorder in the maintenance phase: A systematic review and meta-analysis. 臨床精神薬理. 2021. 24. 9
-
Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Nakao Iwata. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology. 2020. 237. 5. 1459-1470
-
Taro Kishi, Reiji Yoshimura, Yuki Matsuda, Kenji Sakuma, Nakao Iwata. Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. Pharmacopsychiatry. 2020. 53. 3. 122-132
ｍore...
Professional career (1)：
Work history (1)：
- 2018/04 - Fujita Health University School of Medicine
Return to Previous Page
